[go: up one dir, main page]

WO2007038453A3 - Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation - Google Patents

Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation Download PDF

Info

Publication number
WO2007038453A3
WO2007038453A3 PCT/US2006/037332 US2006037332W WO2007038453A3 WO 2007038453 A3 WO2007038453 A3 WO 2007038453A3 US 2006037332 W US2006037332 W US 2006037332W WO 2007038453 A3 WO2007038453 A3 WO 2007038453A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
agent
growth factor
vascular endothelial
endothelial growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/037332
Other languages
French (fr)
Other versions
WO2007038453A2 (en
Inventor
Gholam Ali Peyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Ocular Systems Ltd
Original Assignee
Advanced Ocular Systems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/234,970 external-priority patent/US20070071754A1/en
Priority claimed from US11/348,017 external-priority patent/US20070071756A1/en
Priority claimed from US11/348,465 external-priority patent/US20070072933A1/en
Application filed by Advanced Ocular Systems Ltd filed Critical Advanced Ocular Systems Ltd
Publication of WO2007038453A2 publication Critical patent/WO2007038453A2/en
Publication of WO2007038453A3 publication Critical patent/WO2007038453A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Use of an anti-vascular endothelial growth factor (VEGF) agent for the manufacture of a medicament to ameliorate inflammation at a site in the body that may be the eye, a joint, the brain, etc. or to reduce corneal neovascularization. In one embodiment, one or more other agents, such as non-steroidal anti-inflammatory agents, steroids, etc., may be included with the anti-VEGF agent. The anti-VEGF agent may be bevacizumab, ranibizumab, sunitinib maleate, pegaptanib, etc.
PCT/US2006/037332 2005-09-26 2006-09-26 Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation Ceased WO2007038453A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/234,970 2005-09-26
US11/234,970 US20070071754A1 (en) 2005-09-26 2005-09-26 Method to ameliorate inflammation
US11/348,465 2006-02-06
US11/348,017 US20070071756A1 (en) 2005-09-26 2006-02-06 Delivery of an agent to ameliorate inflammation
US11/348,017 2006-02-06
US11/348,465 US20070072933A1 (en) 2005-09-26 2006-02-06 Delivery of an ocular agent

Publications (2)

Publication Number Publication Date
WO2007038453A2 WO2007038453A2 (en) 2007-04-05
WO2007038453A3 true WO2007038453A3 (en) 2007-11-29

Family

ID=37806769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037332 Ceased WO2007038453A2 (en) 2005-09-26 2006-09-26 Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation

Country Status (1)

Country Link
WO (1) WO2007038453A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435510B2 (en) 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
DE102007038730A1 (en) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Evidence of Human Vascular Endothelial Growth Factor
JP5542691B2 (en) † 2007-12-20 2014-07-09 ユニバーシティ オブ サザン カリフォルニア Devices and methods for delivering therapeutic agents
JP2011513229A (en) * 2008-02-21 2011-04-28 イスタ・ファーマスーティカルズ・インコーポレイテッド Ophthalmic NSAID as an adjuvant
EP2379109B1 (en) * 2008-12-16 2020-10-07 Bausch Health Companies Inc. Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN102448459A (en) * 2009-04-15 2012-05-09 意大利癌症研究国立研究所基金会 Use of multi-kinase inhibitors for the treatment of vascular hyperpermeability
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
EP2755600B1 (en) 2011-09-16 2021-03-17 ForSight Vision4, Inc. Fluid exchange apparatus
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
WO2013148305A1 (en) * 2012-03-29 2013-10-03 Xavier University Of Louisiana Method for treating diabetic retinopathy
WO2013188283A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
US8747852B1 (en) * 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP2016523956A (en) * 2013-07-11 2016-08-12 ノバルティス アーゲー Use of VEGF antagonists in the treatment of retinopathy of prematurity
EP3679908B1 (en) 2014-07-15 2024-09-04 ForSight Vision4, Inc. Ocular implant delivery device
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
ES2971096T3 (en) 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Compositions and methods for treating therygium
TWI700085B (en) 2015-06-22 2020-08-01 新源生物科技股份有限公司 Use of ophthalmic formulations of tyrosine kinase inhibitors
CN108430405B (en) 2015-11-20 2021-04-13 弗赛特影像4股份有限公司 Porous structures for sustained release drug delivery devices
AU2017246889B2 (en) 2016-04-05 2021-12-16 Forsight Vision4, Inc. Implantable ocular drug delivery devices
JP7079243B2 (en) 2016-06-02 2022-06-01 エイディーエス セラピューティクス リミテッド ライアビリティ カンパニー Compositions and Methods Using Nintedanib to Improve the Success Rate of Glaucoma Surgery
JP7314155B2 (en) 2017-11-21 2023-07-25 フォーサイト・ビジョン４・インコーポレーテッド FLUID EXCHANGE DEVICE FOR INFLATABLE PORT DELIVERY SYSTEM AND METHOD OF USE THEREOF
EP3813793B1 (en) 2018-05-25 2023-09-20 ADS Therapeutics LLC A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013909A1 (en) * 1997-09-12 1999-03-25 Toagosei Co., Ltd. Corneal neovascularization inhibitors
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
WO2005074942A1 (en) * 2004-02-04 2005-08-18 Retmed Pty Ltd Slow release steroid composition
US20050192429A1 (en) * 2001-04-13 2005-09-01 Rosen Craig A. Vascular endothelial growth factor 2
WO2005084188A2 (en) * 2004-02-25 2005-09-15 Massachusetts Eye & Ear Infirmary Systemic inflammatory markers and age-related macular degeneration (amd)
WO2005110362A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006088650A2 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013909A1 (en) * 1997-09-12 1999-03-25 Toagosei Co., Ltd. Corneal neovascularization inhibitors
US20050192429A1 (en) * 2001-04-13 2005-09-01 Rosen Craig A. Vascular endothelial growth factor 2
US20050058688A1 (en) * 2003-02-22 2005-03-17 Lars Boerger Device for the treatment and prevention of disease, and methods related thereto
WO2005074942A1 (en) * 2004-02-04 2005-08-18 Retmed Pty Ltd Slow release steroid composition
WO2005084188A2 (en) * 2004-02-25 2005-09-15 Massachusetts Eye & Ear Infirmary Systemic inflammatory markers and age-related macular degeneration (amd)
WO2005110362A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
WO2006088650A2 (en) * 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AMANO SHIRO ET AL: "Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization", IOVS, vol. 39, no. 1, January 1998 (1998-01-01), pages 18 - 22, XP008079338 *
BEER P M ET AL: "VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS", RETINA, PHILADELPHIA, PA, US, vol. 26, no. 8, 2006, pages 871 - 876, XP008079356, ISSN: 0275-004X *
DATABASE WPI Week 19, 25 March 1999 Derwent World Patents Index; Class 991, Page 9, AN 1999-229406, XP002437620, KAWAKAMI Y. ET AL.: "Corneal neovascularisation inhibitors" *
KANTOFF PHILIP: "RECENT PROGRESS IN MANAGEMENT OF ADVANCED PROSTATE CANCER", ONCOLOGY, PRR, HUNTINGTON, NY, US, vol. 19, no. 5, April 2005 (2005-04-01), pages 631 - 636, XP008079352, ISSN: 0890-9091 *
MICHELS STEPHAN ET AL: "Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.", OPHTHALMOLOGY JUN 2005, vol. 112, no. 6, June 2005 (2005-06-01), pages 1035 - 1047, XP005825968, ISSN: 1549-4713 *
ROSENFELD PHILIP J ET AL: "OPTICAL COHERENCE TOMOGRAPHY FINDINGS AFTER AN INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR MACULAR EDEMA FROM CENTRAL RETINAL VEIN OCCLUSION", OPHTHALMIC SURGERY, LASERS AND IMAGING, SLACK, INC., THOROFARE, NJ, US, vol. 36, no. 4, July 2005 (2005-07-01) - August 2005 (2005-08-01), pages 336 - 339, XP008079763, ISSN: 1542-8877 *
ROSENFELD PHILIP J ET AL: "OPTICAL COHERENCE TOMOGRAPHY FINDINGS AFTER AN INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION", OPHTHALMIC SURGERY, LASERS AND IMAGING, SLACK, INC., THOROFARE, NJ, US, vol. 36, no. 4, 22 June 2005 (2005-06-22), pages 331 - 335, XP008079762, ISSN: 1542-8877 *
SUGITA S: "Intravitreal anti-inflammatory treatment for uveitis", BRITISH JOURNAL OF OPHTHALMOLOGY 2007 UNITED KINGDOM, vol. 91, no. 2, 2007, pages 135 - 136, XP008079353, ISSN: 0007-1161 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9417238B2 (en) 2009-01-29 2016-08-16 Forsight Vision4, Inc. Posterior segment drug delivery
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Also Published As

Publication number Publication date
WO2007038453A2 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
WO2007038453A3 (en) Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
WO2011151079A3 (en) Preparation for use in ophthalmology and retinal surgery
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
WO2006133216A3 (en) 4-substituted arylamine derivatives and their use in pharmaceutical compositions
EP1934648A4 (en) OPHTHALMOLOGICAL LENS ELEMENT FOR CORRECTING MYOPIA
EP2346520A4 (en) Curcuminoids and its metabolites for the application in ocular diseases
HK1231367A1 (en) Antibody-drug conjugates, their preparation and their therapeutic use
WO2009089260A3 (en) Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
IL182685A0 (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
HK1211599A1 (en) Il-6 antagonists and uses thereof
DK1833799T3 (en) 3-Phenyl-pyrazole derivatives as modulators of 5-HT-2α-serotonin receptor useful for the treatment of diseases related thereto
WO2007130824A3 (en) Fused heterocylic compounds and their use as mglur5 modulators
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
HK1200366A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11ss-17-21-triol-3,20-dione derivatives
WO2011103018A8 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2014031429A3 (en) Liposome formulations
WO2011066417A3 (en) Antibodies and conjugates for modulators of angiogenesis
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2014004936A8 (en) Selectively polymerizable compositions and methods of use in vivo
IL182424A0 (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
IL219534A0 (en) Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
DK2148667T3 (en) Use of cyclohexane hexol derivatives for the treatment of eye diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06815379

Country of ref document: EP

Kind code of ref document: A2